WEBINAR - The strategy behind your journey to GMP with emphasis on linker payload development - Abzena

WEBINAR – The strategy behind your journey to GMP with emphasis on linker payload development

About

We are doing a webinar on the 5th May at 3PM BST/4PM CET.

Register for the webinar here.

In this webinar, we will review the pros and cons of semi-synthetic and synthetic linker payloads as well as discuss the considerations that should be taken when conjugating your linker payload to its antibody, with the ultimate goal of generating successful clinical material. Examples that illustrate how to overcome the challenges of linker payloads will be presented.

Key Learning Objectives

  • Discover the pros and cons of semi-synthetic linker payloads
  • Discover the pros and cons of synthetic linker payloads
  • What to consider in conjugating your linker payload to your antibody
  • Considerations in combining small and large molecules in the GMP environment leading to successful clinical material.

Speaker bios:

Thomas Nittoli, PhD,
Senior Director, R&D Chemistry Therapeutic Proteins, Regeneron

Tom has over 20 years of experience in the pharmaceutical industry and is currently Senior Director of R&D Chemistry. Tom joined Regeneron in 2010 to advance conjugated antibodies and proteins from discovery to development. Since joining Regeneron, he has developed a variety of small molecules for protein conjugation, lead diverse teams of discovery ADC scientists, and lead cGMP synthesis and conjugation campaigns.

Prior to Regeneron, Tom held positions at Pfizer, Wyeth, and CIBA-Giegy. He holds a PhD from the department of chemistry SUNY Stony Brook and was a post-doctoral fellow at the University of Pennsylvania.

Ian Glassford, PhD,
Director Project Management, Abzena

Ian is part of Abzena’s Scientific Leader group, bringing key technical expertise in chemistry and experience with clinical development to provide strategic support for synthetic chemistry and bioconjugation. Ian has significant experience in the design and synthesis of structurally complex small molecules, the synthesis and handling of high potent compounds including R&D and early process development, and project management of small molecule and bioconjugate manufacturing projects, including planning and execution. Ian started his career with GlaxoSmithKline where he worked as a medicinal chemist focused on synthesis of novel therapeutics utilizing structure and fragment-based design. Ian has a Ph.D. in organic chemistry from Temple University.

Interested in our services? Get In Touch